Aims: To evaluate the safety, pharmacokinetics and pharmacodynamics of SAR425899, a novel polypeptide, active as an agonist at both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCR), in healthy volunteers and in overweight/obese patients with type 2 diabetes (T2D).
| INTRODUCTION
Obesity is a global epidemic. In 2016, the World Health Organization estimated that 13% of the world's adult population was obese. 1 Among the clinical concerns associated with obesity is the high risk of developing type 2 diabetes (T2D). 2 In patients who have progressed to T2D, obesity is associated with an increased risk of developing long-term complications of diabetes. 3, 4 While progress has been made in T2D treatment towards glycaemic control, there is an unmet need for therapies that provide clinically meaningful body weight reduction in combination with glycaemic control, ideally in a single agent.
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Among the pharmacotherapeutic treatments available for T2D, glucagon-like peptide-1 receptor agonists (GLP-1RAs) [5] [6] [7] [8] [9] and sodiumglucose co-transporter-2 inhibitors 10 provide effective weight loss, while also reducing glycated haemoglobin (HbA1c). Treatment with GLP-1RAs results in substantial weight loss in patients with T2D or obesity, primarily by increasing feelings of satiety and consequently reducing energy intake [11] [12] [13] [14] ; however, an increase in energy expenditure has not been observed. [13] [14] [15] [16] [17] Bariatric surgery, which can result in complete resolution of T2D in some patients and weight loss of 20%, 18, 19 is not a trivial procedure and may not be ideal for all patients 20 ; thus, there remains an unmet need for pharmacological alternatives.
OXM is a postprandially released peptide hormone that activates both the GLP-1 receptor (GLP-1R) and the glucagon receptor (GCR). [21] [22] [23] [24] Its mechanism of action supports the use of dual agonism in the treatment of obesity. [25] [26] [27] The weight-loss effect of OXM is probably mediated by both components: GLP-1 agonism, which reduces energy intake, and GCR agonism, which increases energy expenditure. 22, 28, 29 Clinical studies in healthy normal-weight, overweight, or obese volunteers confirmed that subcutaneously administered OXM reduces body weight and energy intake, delays gastric emptying, and increases energy expenditure. 21, [29] [30] [31] Based on the clinical potential of GLP-1R and GCR dual agonism [32] [33] [34] and available data for other dual agonists, we synthesized novel drug candidates with higher in vitro potency for the GLP-1R than for the GCR and investigated their effects on weight loss compared with pure GLP-1RAs. 35 It has been reported that the right balance between GLP-1R and GCR activation would be necessary for a dual agonist to avoid GCR-induced hyperglycaemia and other potential side effects while maintaining the desired effects of HbA1c-lowering and body weight reduction. 36 From a series of dual agonists, one candidate (SAR425899; Figure S1 in Appendix S1) was selected for clinical development for obesity and T2D treatment.
In the present paper, we report the results of the first in-human trials with SAR425899. We evaluated the safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles in normal-to overweight healthy volunteers after single doses of SAR425899, and in normalto overweight healthy volunteers and overweight/obese patients with T2D after multiple ascending doses of SAR425899.
| METHODS
Single-ascending-dose (SAD) and multiple-ascending-dose (MAD) trials were conducted sequentially at the Charité Research Organisation GmbH in Berlin, Germany. All study participants provided written informed consent. Study protocols were approved by National Health
Authorities and an Independent Ethics Committee. Both trials were performed in accordance with the guidelines established by the Declaration of Helsinki and the International Conference on Harmonization -Good Clinical Practice.
| Trial design

| SAD trial
In the randomized, double-blind, placebo-controlled SAD trial, four overweight healthy male volunteers per dose cohort (active, n = 3; placebo, n = 1) received a single subcutaneous dose of 0.01 or 0.03 mg SAR425899 or placebo on study day 1 in the morning under fasted conditions ( Figure 1A ). Following analysis of these dose cohorts, the study was expanded to include eight additional volunteers (active, n = 6; placebo, n = 2) to receive a single dose of 0.05, 0.075 or 0.1 mg SAR425899 to better assess the adverse event (AE) profile at higher doses.
| MAD trial
The double-blind, randomized, placebo-controlled MAD trial (NCT02411825) was conducted in two parts: in the MAD1 trial, eight normal-to overweight healthy male volunteers (active, n = 6; placebo, The overall treatment duration was chosen to achieve steady-state conditions, at least for the maintenance dose. 
| Participants
| Safety and tolerability
| Pharmacodynamics
In the SAD trial, plasma glucose and insulin levels were determined before and after the mixed-meal test (MMT) on days-1 (baseline) and 1.
In the MAD1 and MAD2 trials, fasting plasma glucose (FPG) and body weight were measured from day 1 until the end-of-study visit.
Postprandial plasma glucose (PPG) and insulin levels were measured after food intake at baseline and on the last day of treatment; measurements were taken after lunch in the MAD1 trial and after the MMT in the MAD2 trial. In the MAD2 trial, post-MMT glucose and insulin area under the curves (AUCs) using the trapezoidal rule were calculated for excursions from pre-MMT values (post-AUC 8-12 h ), excluding patients with an incomplete MMT (MMT intake <100%).
Triglyceride, free fatty acid and total cholesterol levels were assessed before the start of dosing, once during treatment, and on the last day of treatment.
In the MAD2 trial, HbA1c levels were measured at baseline and on the last day of treatment. Ketone bodies (acetoacetic acid and 3-OH-butyrate) were assessed before the start of dosing, once during treatment, and on the last day of treatment.
| Pharmacokinetics
Blood samples were collected at multiple time points after the first and last dose for measurement of SAR425899. Morning trough samples were collected until the last day of dosing. Quantitative 24-hour urine samples were collected before dosing and on days 27-28 in the MAD2 trial.
| Statistical analysis
The sample size for these trials was based on empirical considerations. All data were analysed using SAS version 9.2.
| RESULTS
In the SAD trial, 138 volunteers were screened and 32 healthy male volunteers were randomized and completed the study. In the MAD trial, 129 healthy volunteers and 116 patients with T2D underwent screening; 40 healthy male volunteers and 36 men and women with T2D were included. The baseline characteristics of study participants are described in Table 1 . In the MAD1 trial, 32 of 40 volunteers reported at least one AE (Table S1 ). The most frequent side effects were gastrointestinal disorders (dyspepsia, nausea and vomiting) and decreased appetite, observed particularly in treatment groups C, D and E (Table S1 ). Very few AEs were reported in the lower dose groups (groups A and B).
Vomiting was reported by three participants in group C and two in group E. One participant discontinued in group C owing to repeated vomiting at study day 1. In group E, one participant discontinued because of an increase in alanine aminotransferase levels (meeting a predefined stopping rule) at study day 6. At day 21, heart rate and lipase values were numerically higher in groups A to E compared with placebo ( Figure S2A ; Table S2 and S3). One participant in group A was ADA-positive (with low titre) 3 to 4 weeks after treatment.
| Glucose profiles and body weight
In the SAD trial, a decrease in PPG and insulin levels post-MMT was observed at SAR425899 doses ≥0.03 mg; this effect was not seen in the placebo group ( Figure S3 (Table S1 and S4).
Loss of appetite was reported by two patients in group Y and eight in group Z. For patients whose symptoms started at the initial dose, the duration of appetite loss ranged from 2 to 32 days. Three of the 10 patients with loss of appetite experienced nausea, which began several days after the start of appetite loss; none experienced vomiting. One patient discontinued for personal reasons and one patient withdrew consent after several episodes of vomiting and nausea. Two patients in group Z were withdrawn as a result of elevated lipase levels at days 13 and 21, as lipase increase was a predefined stopping criterion. In these patients, no abdominal pain was reported and lipase levels normalized rapidly after treatment discontinuation. Baseline and change from baseline in lipase, amylase, alanine transaminase and aspartate transaminase in the MAD2 trial are provided in Table S3 .
Heart rate increased in groups Y and Z throughout the treatment period, which differed from placebo. The degree of heart rate increase was less pronounced compared with that seen in the MAD1 trial (Table S2 ) and tended to decline toward the end of treatment ( Figure S2B ). Means of Holter-derived 24-hour average heart rate on days − 1 and 28 were 74.2 and 74.7 bpm in the placebo group, 76.6 and 81.7 bpm in group Y, and 75.4 and 79.6 bpm in group Z (Table S2) .
No injection-site, allergic or hypersensitivity reactions were reported. One patient in group Z tested positive for ADAs (with low titre) 3-4 weeks after the end of treatment.
| Glycaemic variables
Both dose regimens resulted in a significant reduction in FPG from baseline to day 29 compared with placebo (P < 0.05; Table 2 and Figure 3A ). The reduction in mean HbA1c from baseline was also significant in both groups compared with placebo, with an increase of 0.61 mmol/mol (0.06%) from a baseline of 58.47 mmol/mol (7.5%) in the placebo group, a decrease of 0.54% (5.87 mmol/mol) from a baseline of 7.1% (54.1 mmol/mol) in group Y (P < 0.001), and a decrease of 6.40 mmol/mol (0.59%) from a baseline of 7.2% (55.19 mmol/mol) in group Z (P < 0.001; Table 2 ).
In the placebo group, the PPG-AUC values were slightly increased from baseline on days 1 (+1.54 mmol h/L) and 28 (+1.87 mmol h/L).
In contrast, a decrease in PPG-AUC was observed in both SAR425899 treatment groups, with a change from baseline of −0.70 and −7.53 mmolÁh/L on days 1 and 28, respectively, in group Y, and −9.45 and −11.61 mmolÁh/L on days 1 and 28, respectively, in group Figure 3B ). Postprandial insulin-AUC values were higher on day 28 in group Y (change from baseline: 337.63 pmol h/L) but decreased in group Z (change from baseline: −115.66 pmolÁh/L).
| Blood lipids and ketone bodies
Blood lipids and ketone body measurements at baseline and end of study are shown in 
| Body weight
Body weights at baseline were similar in all groups, with a mean (SD) of 100.20 (8.5) kg in the placebo group, 98.82 (13.2) kg in group Y, and 97.64 (16.7) kg in group Z. All groups showed a decrease in body weight throughout the treatment period; the treatment effect in group Z was statistically significant compared with placebo (P < 0.001; Figure 2B ; Table 2 ). The mean (SD) change between days −1 (baseline) and 29 (23 hours after the last dose) was −2.37 (1.71) kg in the placebo group, −2.87 (2.04) kg in group Y and −5.46 (1.98) kg in group Z (Table 2) .
| Pharmacokinetics
The PK measurements for the 0.01-mg dose group in the SAD trial were excluded from the analysis as most plasma concentration values were below the lower limit of quantification. Following the SAD trial, mean maximum (peak) plasma drug concentrations (C max ) of 2.63, 4.91, 6.72 and 9.28 ng/mL and mean AUC 0-24 h of 39.2, 82.3, 112 and 151 ng h/mL were observed for the 0.03-, 0.05-, 0.075-and 0.1-mg SAR425899 dose groups, respectively. The median time to reach maximum (peak) plasma concentration after drug administration (t max ) ranged from 8 to 9.25 hours, and the mean half-life ranged from 11.1 to 17.6 hours across dose groups. PK analysis from the SAD trial showed linear pharmacokinetics, slow absorption and a long half-life, supporting once-daily dosing for the MAD trial.
In the MAD1 trial, C max and AUC 0-24 h increased in a doseproportional manner at steady-state over the maintenance dose range of 0.075-0.2 mg (Table S6 and Figure S4 ). The median t max ranged from 6.0 to 7.0 hours and the mean half-life ranged from 13.1 to (Table S6 ).
In the MAD2 trial, similar half-life times were observed at steadystate (mean: 12.6 to 14 hours) in both dosing groups (Table S6 ).
SAR425899 urine concentrations were below quantification limits at all time points. The mean CL/F was slightly higher compared with in healthy volunteers, resulting in slightly lower AUC 0-24 h and C max values ( Figure S4 ). The higher clearance in patients was probably attributable to the higher body weight in this population. The accumulation ratio was~1.5-to 2-fold in both dose groups, consistent with the long half-life and the frequency of administration (data not shown).
| DISCUSSION
In these first-in-human trials, SAR425899, a novel dual GLP-1R and GCR agonist, was well tolerated and showed favourable PK/PD profiles in healthy volunteers and in patients with T2D. SAR425899 led to a significant reduction in FPG and HbA1c levels in patients with T2D, and promoted body weight loss in overweight healthy volunteers and in overweight/obese patients with T2D. SAR425899
showed dose-proportional exposure, slow subcutaneous absorption, and a long half-life, which makes it optimal for a once-daily regimen.
SAR425899 was well tolerated after single administration in healthy normal-to overweight participants, and after multiple administrations in healthy normal-to overweight healthy participants and in overweight/obese patients with T2D, with an acceptable safety profile. The most common AEs were gastrointestinal, and were less pronounced in patients with T2D compared with healthy volunteers.
Nausea and vomiting were the dose-limiting factors in healthy volunteers in both the SAD and MAD trials. The highest tolerated dose in the SAD trial was 0.1 mg; this could be increased up to 0.2 mg through the introduction of uptitrating regimens. The incidence of immunogenicity was low.
As glucagon acts as a counter-regulatory hormone to insulin, -100 (Table S7) . Repeated administrations of SAR425899 at 0.18 mg in the MAD2 trial resulted in average trough (measured concentration at the end of a dosing interval at steadystate; C trough ) and peak (C max ) plasma concentrations of 8 and 16 ng/ mL, respectively. SAR425899 is 99.8% bound to plasma proteins; therefore, the estimated unbound C trough and C max of SAR425899 are 3.64 and 7.28 pM, respectively, which provides adequate coverage of the EC 50 on both receptors (Table S7 ). As GCR stimulation can promote hepatic lipolysis and ketone body formation, the elevation of plasma ketone bodies observed in the high-dose regimen (group Z) in the MAD2 trial is suggestive of GCR target engagement. 39, 40 Weight loss is induced by GLP-1RAs through inhibition of increased satiety and reduced food intake, while GCR stimulation is hypothesized to promote weight loss through an increase in energy expenditure, which has been documented in humans after GCR stimulation. 41, 42 The combined effect of GCR stimulation and GLP-1R
agonism is expected to result in weight loss superior to that observed for selective GLP-1RAs alone. 36 The effect of SAR425899 on weight loss observed in the 4-week trial period demonstrates the potential for efficacy in weight loss treatment. 9, 15 Although weight loss was not clearly dose-dependent in healthy volunteers, the maximal change in body weight was seen at the highest dose (0.2 mg). Weight loss did not plateau during the treatment period, suggesting it could continue beyond 4 weeks.
These results support the potential of SAR425899 as a therapeutic agent for patients with T2D and obesity. As these were exploratory, phase I studies with a small sample size and low statistical power, further trials are required to confirm these results in larger, long-term, higher-powered studies, and in particular, to compare the efficacy and safety of SAR425899 versus pure GLP-1RAs in head-tohead studies.
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